Literature DB >> 1566569

Evidence that the amantadine-induced, M2-mediated conversion of influenza A virus hemagglutinin to the low pH conformation occurs in an acidic trans Golgi compartment.

F Ciampor1, P M Bayley, M V Nermut, E M Hirst, R J Sugrue, A J Hay.   

Abstract

Amantadine treatment of cells infected with H7 strains of influenza A viruses causes an M2 protein-mediated conversion of hemagglutinin (HA) from its native to its low pH conformation. Immunofluorescence and electron microscopic observations showed that the structural alteration and hence drug action occur shortly after HA exits from the Golgi complex during its passage through the strans Golgi region. Using the DAMP/anti-DNP pH probe it is evident that virus infection causes increased acidity of the trans Golgi region and that vesicles containing low pH HA in amantadine-treated virus-infected cells are particularly acidic. These results indicate therefore that the alteration in HA is the direct consequence of exposure to an adverse low pH and provide further support for the conclusion that the M2 protein, the target of amantadine action, is involved in regulating vesicular pH, a function important for the correct maturation of the HA glycoprotein.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1566569     DOI: 10.1016/0042-6822(92)90730-d

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  74 in total

1.  Definitive assignment of proton selectivity and attoampere unitary current to the M2 ion channel protein of influenza A virus.

Authors:  T I Lin; C Schroeder
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

2.  Identification of a membrane targeting and degradation signal in the p42 protein of influenza C virus.

Authors:  A Pekosz; R A Lamb
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Effect of cytoplasmic tail truncations on the activity of the M(2) ion channel of influenza A virus.

Authors:  K Tobler; M L Kelly; L H Pinto; R A Lamb
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

4.  Influence of an additional amino group on the potency of aminoadamantanes against influenza virus A. II - Synthesis of spiropiperazines and in vitro activity against influenza A H3N2 virus.

Authors:  Christos Fytas; Antonios Kolocouris; George Fytas; Grigoris Zoidis; Charalampos Valmas; Christopher F Basler
Journal:  Bioorg Chem       Date:  2010-09-21       Impact factor: 5.275

5.  Assembly of the m2 tetramer is strongly modulated by lipid chain length.

Authors:  Sandra Schick; Lirong Chen; Edwin Li; Janice Lin; Ingo Köper; Kalina Hristova
Journal:  Biophys J       Date:  2010-09-22       Impact factor: 4.033

Review 6.  Influenza A viruses: why focusing on M2e-based universal vaccines.

Authors:  Seyyed Mahmoud Ebrahimi; Majid Tebianian
Journal:  Virus Genes       Date:  2010-11-17       Impact factor: 2.332

7.  NP, PB1, and PB2 viral genes contribute to altered replication of H5N1 avian influenza viruses in chickens.

Authors:  Jamie L Wasilenko; Chang Won Lee; Luciana Sarmento; Erica Spackman; Darrell R Kapczynski; David L Suarez; Mary J Pantin-Jackwood
Journal:  J Virol       Date:  2008-02-27       Impact factor: 5.103

8.  Signal peptide cleavage and internal targeting signals direct the hepatitis C virus p7 protein to distinct intracellular membranes.

Authors:  Stephen Griffin; Dean Clarke; Christopher McCormick; David Rowlands; Mark Harris
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

9.  Role of conserved glycosylation sites in maturation and transport of influenza A virus hemagglutinin.

Authors:  P C Roberts; W Garten; H D Klenk
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

10.  Functional studies indicate amantadine binds to the pore of the influenza A virus M2 proton-selective ion channel.

Authors:  Xianghong Jing; Chunlong Ma; Yuki Ohigashi; Fernando A Oliveira; Theodore S Jardetzky; Lawrence H Pinto; Robert A Lamb
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-31       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.